Equities

Faron Pharmaceuticals Oy

FARN:LSE

Faron Pharmaceuticals Oy

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)167.50
  • Today's Change5.00 / 3.08%
  • Shares traded4.11k
  • 1 Year change-1.47%
  • Beta2.1981
Data delayed at least 20 minutes, as of Feb 06 2026 15:56 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy1
Outperform3
Hold0
Sell0
Strong Sell1

Share price forecast

The 6 analysts offering 12 month price targets for Faron Pharmaceuticals Oy have a median target of 286.45, with a high estimate of 434.01 and a low estimate of 69.44. The median estimate represents a 71.01% increase from the last price of 167.50.
High159.1%434.01
Med71.0%286.45
Low-58.5%69.44

Earnings history & estimates

Faron Pharmaceuticals Oy reported annual 2024 losses of -0.290 per share on Feb 27, 2025.
Average growth rate-4.02%
More ▼

Revenue history & estimates

Faron Pharmaceuticals Oy did not report revenues for the full year 2024. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.